DFTX's Quality Score fell 1 point on Tue, Nov 10, to -1. It closed away from its high of the day.
Follow DFTX's trial news. Pro members can get an alert when Definium Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 14% from Nov 5 to Nov 10.
| Holding it back | 58.3% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
ReportLast night: the results are out. Past reports ›
Tue Nov 10: Stifel Healthcare Conference 2026Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -1.5% on average, higher 1 of 4 times.
The company says its cash lasts into 2030 (8-K, Nov 9).
No shelf registration or at-the-market program on file in the last three years.
Chief Medical Officer Daniel Karlin sold 10,853 shares on Sep 25, under a planned sale. 13 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
DFTX is #150 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 150 |
Share count against a year before: DFTX +58%, RGC +0%.
Expected to report Thu Mar 4, after the close (in 114 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease in net loss was primarily attributable to a gain from the change in fair value of the Company’s 2022 USD financing warrants and higher interest income, partially offset by increased operating expenses.”
DFTX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily attributable to an $8.8 million increase in personnel-related costs associated with the expansion of the Company’s research and development organization, a $5.9 million increase in expenses related to the DT120 development program, and a $0.6 million increase in preclinical and other program expenses, partially offset by a $0.2 million decrease in DT402 program expenses.”
From its results filing (SEC filing · Nov 9)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -2.7% | -2.1% | not yet |
| Aug 6, 2026 | +0.3% | 0.0% | -4.8% |
| May 7, 2026 | -1.5% | -5.0% | -8.0% |
RSI 48.4, MACD above signal, below its 50-day, above its 200-day. Not scored.
Officers and directors with a Form 4 in the last 12 months.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
DFTX scores -1 today, which Breakaway calls Poor. It is #150 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 14% from Nov 5 to Nov 10. Shares: 58.3% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
DFTX scores -1 today, which Breakaway calls Poor (below zero). That is #150 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DFTX's -1.
Expected to report Thu Mar 4, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DFTX closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.